載入...
p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1‐NF‐κB pathway in human ovarian cancer cells
Platinum‐based therapeutic strategies have been widely used in ovarian cancer treatment. However, drug resistance has greatly limited therapeutic efficacy. Recently, tolerance to cisplatin has been attributed to other factors unrelated to DNA. p62 (also known as SQSTM1) functions as a multifunctiona...
Na minha lista:
| 發表在: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497928/ https://ncbi.nlm.nih.gov/pubmed/28498503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13276 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|